Physician profile
Carmin Appolon
NPI 1124052394
$6,339.76
in general payments reported to CMS, 2019-2025
15 companies · $464 in 2025
The $464 reported for 2025 was more than what 92% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $652 · 2021: $939 · 2022: $803 · 2023: $1,471 · 2024: $1,174 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,108.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,298.92 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,282.80 | 2019-2025 | Invega Sustenna |
| Alkermes, INC. | $1,016.56 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $807.36 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $616.66 | 2020-2025 | Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $512.33 | 2020-2025 | Uzedy, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $272.38 | 2019-2021 | |
| Bioxcel Therapeutics, INC. | $119.04 | 2023 | Igalmi |
| Abbvie INC. | $98.90 | 2024-2025 | |
| Brainsway USA INC | $72.89 | 2019-2022 | |
| Allergan, INC. | $66.35 | 2019 | |
| Indivior INC. | $64.84 | 2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.04 | 2020-2024 | Caplyta |
| Janssen Scientific Affairs, LLC | $28.14 | 2025 | Invega Sustenna |
| Corium, LLC | $27.55 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmin Appolon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.